Pharmacomechanical thrombectomy with Angiojet in acute arterial occlusions: A prospective study among the results and outcomes
Vascular · 2025
DOI: 10.1177/17085381241237559 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vascular, 2025. Verfasst von Rafael de Athayde Soares und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Vascular and Endovascular Surgery, Hospital do Servidor Público Estadual de São Paulo, Sao Paulo, Brazil. Hauptthemen laut MEDLINE: Thrombectomy, Peripheral Arterial Disease, Endovascular Procedures, Ischemia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Objective
The main objective of this present paper was to evaluate the results and outcomes of patients with acute limb ischemia (ALI) submitted to pharmacomechanical thrombectomy (PMT) endovascular surgery with Angiojet, regarding the number of cycles/pumps.
Methods
Prospective, consecutive cohort study of ALI patients submitted to PMT endovascular intervention subdivided into two groups according to the number of cycles in the Angiojet technique: Group 1 higher than 150 cycles/second and Group 2 lesser than 150 cycles/second (cycles/s).
Results
Overall, 92 patients with ALI submitted to PMT were evaluated. Two groups of patients were identified: Group 1 higher than 150 cycles/s with 60 patients and Group 2 lesser than 150 cycles/s with 32 patients. The overall mortality rate (OMR) was 15.1% (13 patients) in total cohort within the first 30 days. Group 1 had a higher OMR than Group 2 (16.1% vs 9.3%, p = 0.007). There were 4 cases of hematuria (4.3%), all of them in Group 1. We have performed a Kaplan–Meier regarding limb salvage rates: Group 1 had 85% and Group 2 had 95.7% at 1057 days. P = 0.081. Among the factors evaluated, the following were related to overall mortality rate: PMT with higher >150 cycles/s (HR = 7.17, p = 0.007, CI: 1.38–8.89), COVID-19 infection (HR = 2.75, p = 0.010, CI = 1.73–5.97), and post-operative acute kidney injury (HR = 2.97, p < 0.001, CI = 1.32–8.13). Among the factors evaluated, the following was related to limb loss: post-operative acute kidney injury (HR = 4.41, p = 0.036, CI: 1.771–7.132), probably because patients experiencing limb loss have a higher incidence of acute renal insufficiency due to higher circulating myoglobin higher hemolysis from the increased Angiojet cycles inducing rhabdomyolysis.
Conclusion
PMT with Angiojet is a safe and effective therapy in patients with ALI. However, patients receiving greater than 150 cycles/s were noted to have higher rates of acute kidney injury and mortality. This is likely reflective of increased thrombus burden and higher rates of hemolysis. Acute kidney injury, greater than 150 cycles/s, and COVID-19 infection were the variables with the strongest association to perioperative mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Vascular and Endovascular Surgery, Hospital do Servidor Público Estadual de São Paulo, Sao Paulo, Brazil.
ORCID-Profile: Rafael de Athayde Soares
Zitieren
APA
Soares, R. A., Campos, A. B. C., Portela, M. V. V., Brienze, C. S., Brancher, G. Q. B., & Sacilotto, R. (2025). Pharmacomechanical thrombectomy with Angiojet in acute arterial occlusions: A prospective study among the results and outcomes. Vascular. https://doi.org/10.1177/17085381241237559
Vancouver
Soares RA, Campos ABC, Portela MVV, Brienze CS, Brancher GQB, Sacilotto R. Pharmacomechanical thrombectomy with Angiojet in acute arterial occlusions: A prospective study among the results and outcomes. Vascular. 2025. doi:10.1177/17085381241237559
BibTeX
@article{Soares2025,
author = {Soares, Rafael de Athayde and Campos, Ana Beatriz Campelo and Portela, Matheus Veras Viana and Brienze, Carolina Sabadoto and Brancher, Giovana Quarentei Barros and Sacilotto, Roberto},
title = {Pharmacomechanical thrombectomy with Angiojet in acute arterial occlusions: A prospective study among the results and outcomes},
journal = {Vascular},
year = {2025},
doi = {10.1177/17085381241237559}
}
EUVIMED